Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of bioequivalence between HD201 and trastuzumab sourced in the European Union (EU-trastuzumab)

Next Previous
Trial Profile

A study of bioequivalence between HD201 and trastuzumab sourced in the European Union (EU-trastuzumab)

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer; Gastric cancer
  • Focus First in man; Pharmacokinetics

    • Most Recent Events

    • 08 Mar 2018 New trial record
    • 01 Mar 2018 Primary endpoint (AUC0-infinity) has been met as per the results published in the Clinical Therapeutics.
    • 01 Mar 2018 Results assessing bioequivalence published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top